MASS 8-K
908 Devices Inc. (MASS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including zip code)
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last reports)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item 5.02 | Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. |
On June 12, 2025, Marcia Eisenberg resigned from the Board of Directors (the “Board”) of 908 Devices Inc. (the “Company”) and the Compensation Committee of the Board. Her resignation was effective on June 12, 2025 at 5:00 p.m. Eastern Time. Her decision to resign from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices and follows the Company’s recent sale of its bioprocessing product portfolio.
On June 13, 2025, Christopher D. Brown was appointed to the Board to fill the vacancy created following Ms. Eisenberg’s resignation. Dr. Brown will serve as a Class III director, with a term expiring at the Company’s 2026 annual meeting of stockholders.
Dr. Brown has been Vice President of R&D, Analytics at Repligen, Inc. (NASDAQ: RGEN) since March 2025, when Repligen, Inc. purchased the Company’s bioprocessing product portfolio. Previously, Dr. Brown was a co-founder of the Company, and served as its Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 to March 2025. Prior to co-founding the Company, Dr. Brown was a platform architect at Apple Inc. (NASDAQ: AAPL) leading investigations in future-gen health technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific Inc. (NYSE: TMO) and from 2005 until 2010 he was Senior Director of Product Development and Engineering at Ahura Scientific, Inc. Dr. Brown holds a B.Sc. in Mathematics/Chemistry from Brandon University, and a Ph.D. in Chemistry from Dalhousie University where he specialized in statistical and machine learning methods for chemical data.
Following his resignation from employment with the Company in March 2025, Dr. Brown entered into a consulting agreement with the Company, dated March 17, 2025 (the “Consulting Agreement”), whereby he continues to provide services to the Company as reasonably requested with respect to his expertise in research & development, technology, and business strategy to support current operations and future planning, and other related matters. In connection with his entry into the Consulting Agreement and continued service to the Company, Dr. Brown’s outstanding equity awards continue to vest. Dr. Brown is not entitled to receive any cash compensation under the Consulting Agreement.
Dr. Brown is entitled to receive annual cash compensation, an initial, one-time equity award, and an annual equity award in accordance with the Company’s Non-Employee Director Compensation Policy (the “Policy”). However, Dr. Brown has waived the right to receive compensation pursuant to the Policy in connection with his initial service as a non-employee director.
In connection with his appointment, Dr. Brown and the Company also entered into the Company’s standard form of indemnification agreement for directors.
There are no arrangements or understandings between Dr. Brown and any other persons pursuant to which Dr. Brown was elected as a director. In addition, there are no family relationships between Dr. Brown and any other director or executive officer of the Company and Dr. Brown has no direct or indirect material interest in any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.
On June 13, 2025, the Board appointed Fenel M. Eloi to the Compensation Committee of the Board, to fill the vacancy created upon Ms. Eisenberg’s resignation. The Board determined that Mr. Eloi is “independent” as that term is defined in the applicable Nasdaq rules, and that he meets the requirements of a “non-employee director” pursuant to Rule 16b-3 under the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On June 16, 2025, the Company issued a press release announcing the appointment of Dr. Brown as a director. The press release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release dated June 16, 2025 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| 908 DEVICES INC. |
| June 16, 2025 | By: | /s/ Michael S. Turner |
| Michael S. Turner | ||
| Chief Legal and Administrative Officer |
Exhibit 99.1
908 Devices Appoints Christopher D. Brown to its Board of Directors
BOSTON, June 16, 2025 – 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (Nasdaq: RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately.
Dr. Brown co-founded 908 Devices and served as the company’s Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company’s bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (Nasdaq: AAPL) leading investigations in future-gen health technologies. Prior to Apple, from April 2010 to October 2010, he was a Senior Director at Thermo Fisher Scientific Inc. (NYSE: TMO) and from 2005 until 2010 he led product development and engineering at Ahura Scientific, which was acquired by Thermo Fisher Scientific.
Dr. Brown holds a bachelor’s degree in mathematics and chemistry from Brandon University, and a PhD in chemistry from Dalhousie University where he specialized in statistical and machine learning methods for chemical data.
“Chris played a pivotal role in shaping our product strategy and assembling the exceptional team that continues to advance our technology today,” said Kevin J. Knopp, CEO and Co-founder, 908 Devices. “I’m excited that we can continue to benefit from his expertise, vision, and leadership in his new role on the Board.”
“I’m delighted that Chris is now a board member,” said Kevin Hrusovsky, Chairman of 908 Devices. “His deep expertise in advanced analytical technologies and long-standing commitment to innovation will be a valuable asset to the Board and to the company.”
About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in vital health and safety applications, such as the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.
Forward Looking Statements for 908 Devices
This press release includes "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under "Risk Factors" and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Media Contact
Barbara Russo
Investor Contact
Carrie Mendivil
###